Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Vasodilator

PreclinicalSmall molecule

IIndiana University

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic Heart Disease (IHD)Recruiting

Ischemic Heart Disease (IHD)Preclinical

Recruiting

Timeline

Expected Milestones

Q1 2029

PreclinicalRecruiting

Ischemic Heart Disease (IHD)

NCT06854458

Clinical

Trials by Indication[1]

Heart Failure1 trial

B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial

Completed·IIndiana University·Phase 2·NCT03136198·130 enrolled

Ischemic Heart Disease (IHD)1 trial

The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States (SPINS2) Study

Recruiting·BBrigham and Women's Hospital·Preclinical·NCT06854458·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Vasodilator. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vasodilator compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vasodilator. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Indiana University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIndiana University

Related News